Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA SNORA62, a member of the SNORA6 family, is a non-coding RNA classified as an H/ACA box snoRNA. H/ACA snoRNAs, including SNORA62, localize to the nucleolus and assemble with specific proteins to form small nucleolar ribonucleoproteins (snoRNPs). Their primary role is to guide the site-specific pseudouridylation of ribosomal RNA (rRNA), an essential post-transcriptional modification that contributes to ribosome biogenesis, function, and stability[1][2][3]. snoRNAs can also participate in other processes such as RNA processing and global regulation of gene expression, but no evidence places SNORA62 as a direct therapeutic target or as a validated biomarker in clinical settings. The biological relevance of SNORA62, in common with other snoRNAs, is emerging in cancer and other disease research, mainly through their impact on ribosome function and potential for dysregulation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA SNORA62 (SNORA62).